The most trusted news from Massachusetts

Provided by AGP

Got News to Share?

The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on May 14, 2026

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Acquia Launches Fair Trade Initiative, Committing 2% of Every Eligible Partner Deal to the Drupal Association
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Acronis Appoints Jim Tedesco as Chief Revenue Officer
Merlin Unveils Plans for AI-Powered Autonomy for Commercial Cargo Aircraft
 ElevateBio Data at ASGCT 29th Annual Meeting Showcase Expanded Gene Editing Platform and Services Spanning New Modalities, AI Discovery, and LNP Delivery
Merlin, Inc. Reports First Quarter 2026 Results
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
Destination XL Group, Inc. to Announce First Quarter 2026 Financial Results on Thursday, May 28, 2026
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Akamai Technologies Announces Intent to Acquire LayerX, Advancing Its Workforce Security Strategy with AI Usage Control
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Share us

on your social networks:

Sign up for:

The Boston Examiner

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.